Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
0(0%)
Results Posted
50%(2 trials)
Terminated
2(20%)

Phase Distribution

Ph early_phase_1
1
10%
Ph phase_1
3
30%
Ph not_applicable
1
10%
Ph phase_3
3
30%
Ph phase_2
1
10%
Ph phase_4
1
10%

Phase Distribution

4

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution10 total trials
Early Phase 1First-in-human
1(10.0%)
Phase 1Safety & dosage
3(30.0%)
Phase 2Efficacy & side effects
1(10.0%)
Phase 3Large-scale testing
3(30.0%)
Phase 4Post-market surveillance
1(10.0%)
N/ANon-phased studies
1(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(4)
Terminated(2)
Other(4)

Detailed Status

unknown4
Completed4
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (10.0%)
Phase 13 (30.0%)
Phase 21 (10.0%)
Phase 33 (30.0%)
Phase 41 (10.0%)
N/A1 (10.0%)

Trials by Status

unknown440%
completed440%
terminated220%

Recent Activity

Clinical Trials (10)

Drug Details

Intervention Type
DRUG
Total Trials
10